Development and assessment of 3D-printed individual applicators in gynecological MRI-guided brachytherapy

Helena Barbara Zobec Logar; Robert Hudej; Barbara Šegedin

doi:10.5114/jcb.2019.84741

Development and assessment of 3D-printed individual applicators in gynecological MRI-guided brachytherapy

J Contemp Brachytherapy. 2019 Apr;11(2):128-136. doi: 10.5114/jcb.2019.84741. Epub 2019 Apr 29.

Authors

Helena Barbara Zobec Logar^{1

2}, Robert Hudej¹, Barbara Šegedin^{1

2}

Affiliations

¹ Department of Radiation Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
² Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.

Abstract

Purpose: To evaluate the clinical use of 3D printing technology for the modelling of individual applicators for advanced gynecological tumors in magnetic resonance imaging (MRI)-based brachytherapy (BT).

Material and methods: We tested individually designed 3D-printed applicators in nine patients with advanced gynecological cancer. Before BT was performed, all patients were treated with external beam radiotherapy (EBRT). The most common indication for individualized BT was advanced gynecological tumors where the use of standard BT applicators was not feasible. Other indications were suboptimal dose-volume histogram (DVH) parameters for high-risk clinical target volume (CTV-T_HR) at the first BT (V₁₀₀ ≤ 90% of CTV-T_HR volume and D₉₈ ≤ 80%, D₉₀ ≤ 100%, and D₁₀₀ ≤ 60% of dose aim). The EQD₂ dose aim to the target volume D₉₀ CTV-T_HR per one BT fraction was 20 Gy for cervical or recurrent endometrial cancer and 16 Gy for vaginal cancer patient. The first BT with the standard applicator in situ was used as the virtual plan for designing a 3D-printed applicator. The next BT was performed with a 3D-printed applicator in situ. The primary endpoint was to improve CTV-T_HR DVH parameters without exceeding the dose to the organs at risk (OARs).

Results: All DVH parameters for CTV-T_HR were significantly higher with the use of an individually designed applicator. Mean D₉₀ CTV-T_HR improved from 14.1 ±5.4 Gy to 22.0 ±2.5 Gy and from 7.1 Gy to 16.2 Gy for cervical/recurrent endometrial and vaginal cancer, respectively (p < 0.001). The mean D_2cm³ bladder, rectum, sigmoid, and bowel dose was within institutional dose constraints, and increased from 13.0 ±1.5 Gy to 13.6 ±1.5 Gy (p = 0.045), 10.8 ±1.2 Gy to 11.7 ±1.3 Gy (p = 0.004), 8.9 ±3.2 Gy to 10.3 ±3.3 Gy (p = 0.008), and 8.7 ±3.8 Gy to 9.2 ±3.1 Gy (p = 0.2).

Conclusions: With the use of individual 3D-printed applicators, all DVH parameters for CTV-T_HR significantly improved without compromising the dose constraints for the OARs.

Keywords: 3D printing; gynecological cancer; image-guided brachytherapy.